Literature DB >> 27357717

Nailfold capillaroscopy assessment of microcirculation abnormalities and endothelial dysfunction in children with primary or secondary Raynaud syndrome.

Joanna Latuskiewicz-Potemska1, Antonina Chmura-Skirlinska2, Ryszard J Gurbiel2,3, Elzbieta Smolewska4.   

Abstract

Raynaud syndrome (RS) manifests as episodes of transient spasms of peripheral blood vessels, most often in response to cold. The reason of that symptom (primary RS (pRS)) usually cannot be found but may be accompanied by some autoimmune diseases (secondary RS (sRS)). In this study, we assessed microcapillary status and serum concentrations of chosen cytokines, adhesive molecules, and nitric oxide (NO) in patients with pRS and sRS in comparison with healthy children. Eighty-six patients with RS were enrolled into the study, including 52 with pRS and 34 with sRS. The control group consisted of 29 healthy children. A decrease in myorelaxative and anticoagulant abilities was observed, with simultaneous prevalence of vasopressor substances and procoagulative activity. Therefore, several important factors such as endothelin-1 (ET-1), E-selectin (E-sel), interleukin-18 (IL-18), and nitrogen oxide (NO) were also analyzed. Two types of capillaroscopy status were determined: normal and microangiopathic. There was a significant relationship between presence of microangiopathy and higher serum ET-1 (p = 0.018) and E-sel (p = 0.021) levels. Similarly, we have found a correlation between presence of ANA and higher ET-1 (p = 0.005), but not E-sel (p = 0.241). In patients with pRS, we found significant relationship between ANA and higher ET-1 (p = 0.008). No such relations were observed in sRS patients. Our data indicates that external factor-induced vasoconstrictive effects dominated in pRS, whereas in sRS in the course of connective tissue diseases, it was accompanied by coexistent vasodilation due to endothelial dysfunction. The latter phenomenon is at least partially dependent on insufficient NO release.

Entities:  

Keywords:  Capillaroscopy; Connective tissue disease; Endothelium; Microcirculation; Raynaud syndrome

Mesh:

Substances:

Year:  2016        PMID: 27357717     DOI: 10.1007/s10067-016-3340-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  43 in total

Review 1.  Beauty and the beast. The nitric oxide paradox in systemic sclerosis.

Authors:  M Matucci Cerinic; M B Kahaleh
Journal:  Rheumatology (Oxford)       Date:  2002-08       Impact factor: 7.580

2.  Microvascular abnormalities in capillaroscopy correlate with higher serum IL-18 and sE-selectin levels in patients with type 1 diabetes complicated by microangiopathy.

Authors:  Anna Kuryliszyn-Moskal; Artur Dubicki; Wiesław Zarzycki; Anna Zonnenberg; Maria Górska
Journal:  Folia Histochem Cytobiol       Date:  2011       Impact factor: 1.698

3.  Increased production of nitric oxide stimulated by interleukin-1beta in peripheral blood mononuclear cells in patients with systemic sclerosis.

Authors:  T Yamamoto; Y Sawada; I Katayama; K Nishioka
Journal:  Br J Rheumatol       Date:  1998-10

4.  Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease.

Authors:  Sanjay Rajagopalan; Dana Pfenninger; Christine Kehrer; Anjan Chakrabarti; Emily Somers; Robert Pavlic; Debabrata Mukherjee; Robert Brook; Louis G D'Alecy; Mariana J Kaplan
Journal:  Arthritis Rheum       Date:  2003-07

Review 5.  Nitric oxide function in the skin.

Authors:  M-M Cals-Grierson; A D Ormerod
Journal:  Nitric Oxide       Date:  2004-06       Impact factor: 4.427

6.  Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon.

Authors:  A D Blann; K Illingworth; M I Jayson
Journal:  J Rheumatol       Date:  1993-08       Impact factor: 4.666

7.  IL-18 activity in systemic lupus erythematosus.

Authors:  Flavia Favilli; Consuelo Anzilotti; Lucia Martinelli; Paola Quattroni; Salvatore De Martino; Federico Pratesi; Detlef Neumann; Silke Beermann; Daniela Novick; Charles A Dinarello; Diana Boraschi; Paola Migliorini
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

Review 8.  Raynaud's phenomenon: a proposal for classification.

Authors:  E C LeRoy; T A Medsger
Journal:  Clin Exp Rheumatol       Date:  1992 Sep-Oct       Impact factor: 4.473

9.  Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis.

Authors:  C P Denton; M C Bickerstaff; X Shiwen; M T Carulli; D O Haskard; R M Dubois; C M Black
Journal:  Br J Rheumatol       Date:  1995-11

Review 10.  The role of capillaroscopy in differentiation of primary and secondary Raynaud's phenomenon in rheumatic diseases: a review of the literature and two case reports.

Authors:  Sevdalina Nikolova Lambova; Ulf Müller-Ladner
Journal:  Rheumatol Int       Date:  2009-06-23       Impact factor: 2.631

View more
  4 in total

Review 1.  Endothelial dysfunction in cardiovascular disease and Flammer syndrome-similarities and differences.

Authors:  Jens Barthelmes; Matthias P Nägele; Valeria Ludovici; Frank Ruschitzka; Isabella Sudano; Andreas J Flammer
Journal:  EPMA J       Date:  2017-06-06       Impact factor: 6.543

2.  The Association of Flow-Mediated Dilatation and Blood Parameters in Primary Raynaud's Phenomenon.

Authors:  Süheyla Uzun; İlker Kaya
Journal:  Int J Clin Pract       Date:  2022-01-31       Impact factor: 3.149

3.  Impairment of microcirculation and vascular responsiveness in adolescents with primary Raynaud phenomenon.

Authors:  Bernadett Mosdósi; Kata Bölcskei; Zsuzsanna Helyes
Journal:  Pediatr Rheumatol Online J       Date:  2018-03-23       Impact factor: 3.054

4.  The effect of vitamin D3 and thyroid hormones on the capillaroscopy-confirmed microangiopathy in pediatric patients with a suspicion of systemic connective tissue disease-a single-center experience with Raynaud phenomenon.

Authors:  Katarzyna Kapten; Krzysztof Orczyk; Elzbieta Smolewska
Journal:  Rheumatol Int       Date:  2021-06-16       Impact factor: 2.631

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.